--- title: "A tiny implant is calming the eyes that never stop shaking — and China just approved it" date: 2026-11-11 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-brain-chaomu-inys-visual-neurostimulator language: en --- # A tiny implant is calming the eyes that never stop shaking — and China just approved it > China approved i-NYS, an implantable oculomotor neurostimulator from Chaomu Technology (超目科技) for congenital nystagmus (先天性眼球震颤), a condition long considered untreatable, after a 71-patient trial. For most of her life, a child with congenital nystagmus (先天性眼球震颤) sees the world as if it is gently vibrating. There has been no pill, no surgery, no device cleared to stop it. That changed in China in early 2026, when regulators approved a small implant that electrically quiets the muscle signals driving the shake. The device is i-NYS, an implantable oculomotor neurostimulator made by Chaomu Technology (超目科技). It is not a brain-signal decoder in the headline sense of brain-computer interface (脑机接口); it is a neuromodulation implant aimed at the eye muscles. But it sits squarely inside China's push into neural-interface medicine, and the same company is already reaching toward a visual-cortex brain-computer interface (脑机接口) product. Its approval is a clean case study in how a Chinese originator device moves from a clinical idea to a registered implant. ## Key takeaways - i-NYS won NMPA Class III approval on 2026-03-13 (registration No. 国械注准20263120535), the first device cleared specifically for congenital nystagmus (先天性眼球震颤). - It had entered NMPA's innovation "green channel" in 2024-01 and gained a US FDA Humanitarian Use Device designation in 2025-06. - A Chinese multi-center trial across three Beijing hospitals enrolled 71 patients; the developer reports improved foveal fixation time and reduced tremor. - Chaomu (超目科技) has raised several hundred million RMB (≈ US$ tens of millions) across B, C, and D rounds in 2025–2026, with Hong Kong and mainland sovereign-linked funds among the investors. ## The problem it targets Congenital nystagmus (先天性眼球震颤) is a lifelong condition in which the eyes make involuntary, rhythmic, oscillating movements. It usually appears between ages three and six months and never goes away. Patients often have reduced visual acuity, impaired binocular function, and an abnormal head posture as they try to find a stiller viewing angle. Chinese and developer sources put the incidence at roughly 1–3 per 1,000 births, with about 1.3 million patients in China and around 7 million worldwide. Because no definitive treatment existed, it was widely described in ophthalmology as an "incurable" disease. Standard care has been compensatory at best — lenses, prisms, or surgery on the eye muscles that may reduce head posture but does not stop the oscillation. i-NYS takes a different route: it stimulates the neuromuscular interface of the extraocular muscles to suppress the abnormal nerve impulse driving the shake. ## How it was cleared The path to market followed China's innovation-device fast lane. In 2024-01, i-NYS entered NMPA's special review program for innovative medical devices — the "green channel" that gives early, intensive regulatory interaction. On 2026-03-13, NMPA granted the Class III registration (No. 国械注准20263120535), making it the first device approved specifically for this indication. The technology was developed from core work by Professor Wang Lejin (王乐今) of Peking University People's Hospital, a clinician who had pursued the concept for more than two decades. Notably, the device also drew a US FDA Humanitarian Use Device (HUD) designation in 2025-06. An HUD path is reserved for conditions affecting fewer than 8,000 people in the United States per year, and it signals that the agency accepted both the rarity and the non-triviality of the disease — a useful external validation for a China-origin implant. ## What the trial showed The Chinese confirmatory trial ran at three Beijing hospitals — Beijing Chaoyang Hospital, Beijing Tongren Hospital, and Beijing Children's Hospital. According to the developer and China industry reporting, 71 subjects were enrolled: 26 minors aged 8 to under 18, and 45 adults. The reported outcomes were improved foveal fixation time, meaningful reduction of tremor symptoms, and better visual quality, with the developer characterizing the treatment as both effective and safe. Those are the developer's summarized results rather than an independently published peer-reviewed paper, so they should be read as registry and company-reported data, not as confirmed effect sizes. The human story behind the device is also part of the record. A co-founding engineer, Wang Wensi (王文思), a microelectronics professor at Beijing University of Technology, joined the effort in 2018 to turn a clinical hypothesis into an implantable, manufacturable product — a reminder that in Chinese medtech, the bottleneck is often less the science than the engineering and regulatory translation. ## The bigger bet: from eye muscles to visual cortex Chaomu (超目科技) is not stopping at nystagmus. In 2025 the company announced an implantable visual-cortex spatiotemporal-interference neurostimulator — a device intended to deliver functional vision to patients with irreversible blindness by stimulating the visual cortex. That product is described as announced and in development, not yet approved, and it pushes the company from oculomotor neuromodulation into the harder territory of a true visual brain-computer interface (脑机接口). The founder has framed the goal as letting blind patients regain enough functional vision to walk independently and read. The financing supports that stretch. Across 2025 and 2026 the company completed B, C, and D rounds totaling several hundred million RMB (≈ US$ tens of millions), with the C round led by the Hong Kong Investment Corporation (香港投资管理有限公司) and Beyond Ventures (海阔天空创投), and later rounds drawing the Beijing Pharmaceutical and Health Industry Investment Fund and other institutional backers. For a single-indication ophthalmic implant maker, that scale of capital signals an ambition well beyond eye muscles. ## Honest limitations This article is based on Xinhua reporting on the NMPA approval, China industry and science-park reporting on the trial and financing, and the developer's own materials. The 71-patient trial results are summarized by the developer and secondary outlets; no independently peer-reviewed publication with full effect sizes and adverse-event tables was available to this writer, so efficacy and safety claims are reported as the sponsor states them, not as independently confirmed. The US FDA HUD designation is a regulatory status, not an FDA approval for marketing in the United States. The visual-cortex brain-computer interface (脑机接口) product is announced and unapproved; any timeline for it is speculative. Finally, i-NYS is a neuromuscular neurostimulator, not a signal-decoding brain-computer interface (脑机接口) in the strict sense, and readers should not conflate the two. ## What readers can do now - If you follow ophthalmic or neural-interface devices, track the published peer-reviewed trial data for i-NYS — the registry summary is promising, but independent evidence will determine how widely it is adopted outside China. - If you are a clinician seeing nystagmus patients, note that a device-specific approved option now exists in China; check NMPA registration status and eligible hospitals before referring. - If you invest in medtech, watch whether Chaomu's (超目科技) visual-cortex brain-computer interface (脑机接口) reaches a first-in-human trial — that is the step that turns a single-product ophthalmic company into a broader neurotech platform. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-chaomu-inys-visual-neurostimulator Free to quote with attribution and a link to the original.